NCT03493607View on ClinicalTrials.gov

AMO-01 to Treat Adolescents and Adults With Phelan-McDermid Syndrome (PMS) and Co-morbid Epilepsy

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 30, 2018

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Phelan-McDermid SyndromeEpilepsy
Interventions
DRUG

AMO-01

Subjects will receive a single 6-hour intravenous infusion for a total dose administration or 120 mg/m2 of AMO-01.

Trial Locations (2)

10029

Seaver Autism Center for Research and Treatment at Mount Sinai, New York

77030

Texas Children's Hospital, Houston

All Listed Sponsors
lead

Alexander Kolevzon

OTHER

NCT03493607 - AMO-01 to Treat Adolescents and Adults With Phelan-McDermid Syndrome (PMS) and Co-morbid Epilepsy | Biotech Hunter | Biotech Hunter